1. Home
  2. COPR vs RNTX Comparison

COPR vs RNTX Comparison

Compare COPR & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Idaho Copper Corporation Common Stock

COPR

Idaho Copper Corporation Common Stock

N/A

Current Price

$3.41

Market Cap

63.7M

Sector

N/A

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.77

Market Cap

65.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COPR
RNTX
Founded
N/A
2001
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.7M
65.3M
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
COPR
RNTX
Price
$3.41
$0.77
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
93.8K
464.9K
Earning Date
N/A
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
44.16
EPS
N/A
N/A
Revenue
$609,174.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.05
$0.69
52 Week High
$4.16
$2.18

Technical Indicators

Market Signals
Indicator
COPR
RNTX
Relative Strength Index (RSI) 57.20 45.27
Support Level $2.49 $0.71
Resistance Level N/A $0.88
Average True Range (ATR) 0.31 0.06
MACD 0.05 0.01
Stochastic Oscillator 68.66 21.01

Price Performance

Historical Comparison
COPR
RNTX

About COPR Idaho Copper Corporation Common Stock

Idaho Copper Corp is a USA-based company focused on exploring and developing its copper-molybdenum-silver deposit in Idaho, known as the CuMo project. The CuMo project currently consists of several federal unpatented lode mining claims and various patented mining claims. The unpatented lode mining claims and patented claims are situated in an unorganized mining district, in Boise County, Idaho, spanning Sections in Township 7N and 8N, Range 5E and 6E, Boise Meridian.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: